Treatment Patterns, Biochemical Profiles and Clinical Outcomes in Adults With X-Linked Hypophosphatemia

Conditions

• X-linked Hypophosphatemia (XLH)

Eligibility Criteria

Sex

ALL

Age

18 Years - 64 Years

Healthy Volunteers

Not accepted

Interventions

• No treatment given — OTHER
  No treatment given

Study Details

The purpose of this study is to better understand how X-linked hypophosphatemia (XLH) affects the body and daily life. Phosphate levels are critical in managing XLH, we aim to study how these levels change in patients taking burosumab and how they relate to bone health, overall disease burden and XLH-related conditions.

Key Dates

Start date

Jul 7, 2026

Status verified

Apr 2026

Primary completion

Jul 7, 2030

Completion

Jul 7, 2030

Study Design

Enrollment

100 participants (estimated)

Arms

• Arm: Adults with XLH
  Adults with XLH, confirmed genetically or clinically as determined by the investigator, who have been treated with burosumab for at least 90 days prior to the screening/baseline visit and whose treatment is still ongoing will be followed for a maximum of three years, continuing until end of trial visit, withdrawal of consent or loss to follow-up, whichever occurs first.

Primary Outcome Measure

Average Trough Serum Phosphate Concentration [ Time Frame: From baseline to last assessment (Up to 3 years) ]

Central Contacts

• Novo Nordisk
  (+1) 866-867-7178
  [email protected]

Locations (4)

Find similar trials in New Haven, CT